华润双鹤：关于控股子公司通过GMP符合性检查的公告

Core Viewpoint - Recently, China Resources Double Crane announced that its subsidiary, Zhejiang Xinsai Pharmaceutical Co., Ltd., received a GMP compliance inspection notice for the active pharmaceutical ingredients of Fenofibrate and Azilsartan from the Zhejiang Provincial Drug Administration [2] Group 1 - The company has received regulatory approval for two key pharmaceutical products [2] - The approval is significant for the company's production capabilities and market positioning in the pharmaceutical industry [2] - This development may enhance the company's competitive edge in the active pharmaceutical ingredient market [2]